Primary aldosteronism, diagnosed by the aldosterone to renin ratio, is a common cause of hypertension

Clinical Endocrinology

Volumn 59, Issue 4, 2003, Pages 427-430

  Lim, Pitt O ^a   MacDonald, Thomas M ^b  

^a CARDIFF UNIVERSITY   (United Kingdom)

^b UNIVERSITY OF DUNDEE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ALDOSTERONE; ALDOSTERONE ANTAGONIST; ALDOSTERONE SYNTHASE; ANGIOTENSIN; ANTIHYPERTENSIVE AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; ENZYME; NEUROHORMONE; OXYGENASE; RENIN; SODIUM CHLORIDE; SPIRONOLACTONE; STEROIDOGENIC FACTOR 1;

ADRENAL CORTEX ADENOMA; ALDOSTERONE RELEASE; ANTIHYPERTENSIVE THERAPY; BINDING SITE; BLOOD PRESSURE REGULATION; BODY POSTURE; CLINICAL TRIAL; COMPUTER ASSISTED TOMOGRAPHY; DIASTOLIC BLOOD PRESSURE; DRUG TOLERABILITY; EMPIRICISM; ENZYME ACTIVITY; GENETIC POLYMORPHISM; GENETIC SUSCEPTIBILITY; GENETIC VARIABILITY; HEMODYNAMICS; HUMAN; HYPERTENSION; IDIOPATHIC DISEASE; IMMUNOREACTIVITY; INTRON; LOW DRUG DOSE; MONOTHERAPY; MORTALITY; NEGATIVE FEEDBACK; NOTE; PATHOPHYSIOLOGY; PLASMA RENIN ACTIVITY; PREDICTION; PREVALENCE; PRIMARY HYPERALDOSTERONISM; PRIORITY JOURNAL; RISK FACTOR; SCREENING TEST; STROKE;

ALDOSTERONE; ANTIHYPERTENSIVE AGENTS; DIAGNOSTIC TESTS, ROUTINE; HUMANS; HYPERALDOSTERONISM; HYPERTENSION; MUTATION; RENIN; SPIRONOLACTONE;

EID: 0141616478     PISSN: 03000664     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2265.2003.01841.x     Document Type: Note

References (23)

1. Anonymous (1997) The sixth report of the Joint National Committee on prevention, detection, evaluation, and treatment of high blood pressure. Archives of International Medicine, 157, 2413-2446.
2. Chamontin, B., Poggi, L., Lang, T., Menard, J., Chevalier, H., Gallois, H. & Cremier, O. (1998) Prevalence, treatment, and control of hypertension in the French population: data from a survey on high blood pressure in general practice, 1994. American Journal of Hypertension, 11, 759-762.
3. Colhoun, H.M., Dong, W. & Poulter, N.R. (1998) Blood pressure screening, management and control in England: results from the health survey for England 1994. Journal of Hypertension, 16, 747-752.
4. Collins, R., Peto, R., MacMahon, S., Hebert, P., Fiebach, N.H., Eberlein, K.A., Godwin, J., Qizilbash, N., Taylor, J.O. & Hermekens, C.H. (1990) Blood pressure, stroke, and coronary heart disease. Part 2: Short-term reductions in blood pressure: overview of randomised drug trials in their epidemiological context. Lancet, 335, 827-838.
5. Dickerson, J.E., Hingorani, A.D., Ashby, M.J., Palmer, C.R. & Brown, M.J. (1999) Optimisation of antihypertensive treatment by cross-over rotation of four major classes. Lancet, 353, 2008-2013.
6. Ezzati, M., Lopez, A.D., Rodgers, A., Vander Hoorn, S. & Murray, C.J. (2002) Selected major risk factors and global and regional burden of disease. Lancet, 360, 1347-1360.
7. Gordon, R.D. (1994) Mineralocorticoid hypertension. Lancet, 344, 240-243.
8. Hiramatsu, K., Yamada, T., Yukimura, Y., Komiya, I., Ichikawa, K., Ishihara, M., Nagata, H. & Izumiyama, T. (1981) A screening test to identify aldosterone-producing adenoma by measuring plasma renin activity. Results in hypertensive patients. Archives of International Mediciney, 141, 1589-1593.
9. Hood, S., Cannon, J.C., Scanlon, M.J. & Brown, M.J. (2001) Results from the Prevalence of Primary Hyperaldosteronism Measured by Aldosterone to Renin Ratio and Spironolactone Testing (PHArst) Study. 55th Annual Fall Conference and Scientific Sessions of the Council for High Blood Pressure Research, Chicago.
10. Joffres, M.R., Ghadirian, P., Fodor, J.G., Petrasovits, A., Chockalingam, A. & Hamet, P. (1997) Awareness, treatment, and control of hypertension in Canada. American Journal of Hypertension, 10, 1097-1102.
11. Lim, P.O., Dow, E., Brennan, G., Jung, R.T. & MacDonald, T.M. (2000) High prevalence of primary aldosteronism in the Tayside hypertension clinic population. Journal of Human Hypertension, 14, 311-315.
12. Lim, P.O., Jung, R.T. & MacDonald, T.M. (1999) Raised aldosterone to renin ratio predicts anti-hypertensive efficacy of spironolactone. A prospective cohort follow-up study. British Journal of Clinical Pharmacology, 48, 756-760.
13. Lim, P.O., Jung, R.T. & MacDonald, T.M. (2002) Is aldosterone the missing link in refractory hypertension?: aldosterone-to-renin ratio as a marker of inappropriate aldosterone activity. Journal of Human Hypertension, 16, 153-158.
14. Lim, P.O., MacDonald, T.M., Holloway, C., Friel, E., Anderson, N.H., Dow, E., Jung, R.T., Davies, E., Fraser, R. & Connell, J.M. (2002) Variation at the aldosterone synthase (CYP11B2) locus contributes to hypertension in subjects with a raised aldosterone-to-renin ratio. Journal of Clinical Endocrinology and Metabolism, 87, 4398-4402.
15. Lim, P.O., Struthers, A.D. & MacDonald, T.M. (2002) The neurohormonal natural history of essential hypertension: towards primary or tertiary aldosteronism? Journal of Hypertension, 20, 11-15.
16. Lim, P.O., Young, W.F.J. & MacDonald, T.M. (2001) A review of the medical treatment of primary aldosteronism. Journal of Hypertension, 19, 353-361.
17. MacMahon, S., Peto, R., Cutler, J., Collins, R., Sorlie, P., Neaton, J., Abbott, R., Godwin, J., Dyer, A. & Stamler, J. (1990) Blood pressure, stroke, and coronary heart disease. Part 1, Prolonged differences in blood pressure: prospective observational studies corrected for the regression dilution bias. Lancet, 335, 765-774.
18. Marques-Vidal, P. & Tuomilehto, J. (1997) Hypertension awareness, treatment and control in the community: is the 'rule of halves' still valid? Journal of Human Hypertension, 11, 213-220.
19. Montori, V.M., Schwartz, G.L., Chapman, A.B., Boerwinkle, E. & Turner, S.T. (2001) Validity of the aldosterone-renin ratio used to screen for primary aldosteronism. Mayo Clinical Proceedings, 76, 877-882.
20. Rocha, R. & Funder, J.W. (2002) The pathophysiology of aldosterone in the cardiovascular system. Annals of New York Academy of Science, 970, 89-100.
21. Stowasser, M. (2001) Primary aldosteronism: revival of a syndrome. Journal of Hypertension, 19, 363-366.
22. Young, W.F. Jr (1999) Primary aldosteronism: a common and curable formof hypertension. Cardiological Review, 7, 207-214.
23. Young, W.F. Jr (2002) Primary aldosteronism: management issues. Annals of New York Academy of Science, 970, 61-76.